journal article·2018-02-12Open access

Platinum(II) Complex-Nuclear Localization Sequence Peptide Hybrid for Overcoming Platinum Resistance in Cancer Therapy

Marek T. Wlodarczyk, Sylwia A. Dragulska, Olga Camacho-Vanegas, Peter R. Dottino, Andrzej A. Jarzęcki, John A. Martignetti, Aneta J. Mieszawska

Abstract

Platinum therapy represents first line of treatment in many malignancies but its high systemic toxicity limits the therapeutic dosage. Herein, we report the synthesis of carboplatin-like complexes with azide and alkyne functional groups and the formation of a platinum (II) - nuclear localization sequence peptide (Pt-NLS) hybrid to improve the import of platinum (II) complexes directly into the cell's nucleus. The Pt-NLS hybrid successfully enters cells and their nuclei, forming Pt-induced nuclear lesions. The in vitro efficacy of Pt-NLS is high, superior to native carboplatin at the same concentration. The methodology used is simple and cost-effective and most importantly can easily be extended to load the Pt (II) onto other supports, opening new possibilities for enhanced delivery of Pt (II) therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques · Metal complexes synthesis and properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Brooklyn College, The City University of New York, 2900 Bedford Avenue, Brooklyn, New York 11210, United States

Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States

Laboratory for Translational Research, Western Connecticut Health Network, 131 West Street, Danbury, Connecticut 06810, United States

Funding

National Cancer Institute

References (34)

Show source-provided references
1. 10.2174/092986705463762610.2174/0929867054637626 ↗
2. 10.1039/c0dt00292e10.1039/c0dt00292e ↗
3. 10.1016/j.ejphar.2014.07.02510.1016/j.ejphar.2014.07.025 ↗
4. Fichtinger-Schepman A. M. · Cancer Res. · 1987 · 47 · 3000
5. 10.1021/ja01472a00910.1021/ja01472a009 ↗
6. 10.1007/s00280-016-2976-z10.1007/s00280-016-2976-z ↗
7. 10.1016/j.dnarep.2013.04.02010.1016/j.dnarep.2013.04.020 ↗
8. 10.1038/onc.2011.38410.1038/onc.2011.384 ↗
9. 10.1158/1541-7786.MCR-04-003210.1158/1541-7786.MCR-04-0032 ↗
10. 10.1002/jps.1020110.1002/jps.10201 ↗
11. 10.1021/tx050261s10.1021/tx050261s ↗
12. 10.1039/c0dt01758b10.1039/c0dt01758b ↗
13. 10.1021/acs.chemrev.5b0059710.1021/acs.chemrev.5b00597 ↗
14. 10.1039/C6DT01738J10.1039/C6DT01738J ↗
15. 10.1016/j.bmcl.2003.09.01110.1016/j.bmcl.2003.09.011 ↗
16. 10.1021/bc025642l10.1021/bc025642l ↗
17. 10.1016/j.jconrel.2008.10.01810.1016/j.jconrel.2008.10.018 ↗
18. 10.1080/106118602100000184110.1080/1061186021000001841 ↗
19. 10.1016/S0960-894X(01)00623-010.1016/S0960-894X(01)00623-0 ↗
20. 10.1021/bc900065r10.1021/bc900065r ↗
21. 10.2174/156800961666615113021464610.2174/1568009616666151130214646 ↗
22. 10.1016/j.chembiol.2013.08.01010.1016/j.chembiol.2013.08.010 ↗
23. 10.1039/C5CC03180J10.1039/C5CC03180J ↗
24. 10.1039/C4DT02710H10.1039/C4DT02710H ↗
25. 10.1039/c2dt12024k10.1039/c2dt12024k ↗
26. 10.1021/bc049933110.1021/bc0499331 ↗
27. 10.1038/sj.gt.330163510.1038/sj.gt.3301635 ↗
28. 10.1073/pnas.96.1.9110.1073/pnas.96.1.91 ↗
29. Frisch M. J. · 2009
30. 10.1089/cbr.2007.043010.1089/cbr.2007.0430 ↗
31. 10.1016/S1074-5521(02)00189-810.1016/S1074-5521(02)00189-8 ↗
32. 10.1172/JCI11508010.1172/JCI115080 ↗
33. 10.1158/1078-0432.CCR-16-133310.1158/1078-0432.CCR-16-1333 ↗
34. 10.1038/ncomms312610.1038/ncomms3126 ↗